New Phase 3 trial: A Two-Part, Open-Label, Phase 3 Study Evaluating the Efficacy and Safety of WS016 for the Treatment of Hyperkalemia — Waterstone Pharmaceutical (Wuhan) Co., LTD.

1 SOURCE CONFIRMED · FIRST SEEN 2026-10-20 12:00 UTC

KINDCompany

DIRECTION■ Mixed

SOURCES1

ENTITIES0

STORY SIZESTANDALONE

FIRST SEEN2026-10-20 12:00 UTC

LAST UPDATE2026-10-20 12:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.

FULL DISPATCH

Sponsor: Waterstone Pharmaceutical (Wuhan) Co., LTD.; Status: Recruiting; Conditions: Hyperkalemia; Interventions: WS016; Enrollment: 300 (estimated); First posted: 2026-10-20; NCT: NCT07881965

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

NO ENTITY LINKS AT DISPLAY CONFIDENCE YET.

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED

№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-20 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←INFERENCEfilings generate company commentary
META filed 8-K on 2026-10-212026-10-21 00:00 UTC

←INFERENCEfilings generate company commentary
NFLX filed 10-Q on 2026-10-212026-10-21 00:00 UTC

←INFERENCEfilings generate company commentary
TSLA filed 8-K on 2026-10-212026-10-21 00:00 UTC

←INFERENCEfilings generate company commentary
CVX filed 4 on 2026-10-212026-10-21 00:00 UTC

←INFERENCEfilings generate company commentary
JNJ filed 10-Q on 2026-10-212026-10-21 00:00 UTC

←INFERENCEfilings generate company commentary
META filed 4 on 2026-10-212026-10-21 00:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.